CN104693114A - Improved method for preparing betrixaban - Google Patents
Improved method for preparing betrixaban Download PDFInfo
- Publication number
- CN104693114A CN104693114A CN201310664433.2A CN201310664433A CN104693114A CN 104693114 A CN104693114 A CN 104693114A CN 201310664433 A CN201310664433 A CN 201310664433A CN 104693114 A CN104693114 A CN 104693114A
- Authority
- CN
- China
- Prior art keywords
- preparation
- acid
- betrixaban
- magnesium bromide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229950011103 betrixaban Drugs 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 63
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 238000006243 chemical reaction Methods 0.000 claims abstract description 80
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims abstract description 72
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 125000003118 aryl group Chemical group 0.000 claims abstract description 13
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 8
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 84
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 45
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 41
- 125000002524 organometallic group Chemical group 0.000 claims description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 claims description 14
- 230000006872 improvement Effects 0.000 claims description 11
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 10
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 claims description 10
- 239000012046 mixed solvent Substances 0.000 claims description 10
- XWCQLLDGXBLGMD-UHFFFAOYSA-M magnesium;pentane;bromide Chemical compound [Mg+2].[Br-].CCCC[CH2-] XWCQLLDGXBLGMD-UHFFFAOYSA-M 0.000 claims description 7
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- IPSRAFUHLHIWAR-UHFFFAOYSA-N zinc;ethane Chemical group [Zn+2].[CH2-]C.[CH2-]C IPSRAFUHLHIWAR-UHFFFAOYSA-N 0.000 claims description 7
- 239000000376 reactant Substances 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 5
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 claims description 5
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 4
- LZSZSURMDPHQQA-UHFFFAOYSA-N 1,1'-biphenyl;zinc Chemical compound [Zn].C1=CC=CC=C1C1=CC=CC=C1 LZSZSURMDPHQQA-UHFFFAOYSA-N 0.000 claims description 3
- HLBOAQSKBNNHMW-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine Chemical compound COC1=CC=CC(C=2C=NC=CC=2)=C1 HLBOAQSKBNNHMW-UHFFFAOYSA-N 0.000 claims description 3
- CDEMHJCJMMOFMB-UHFFFAOYSA-M ClC1=CC=C([Mg]Br)C=C1 Chemical compound ClC1=CC=C([Mg]Br)C=C1 CDEMHJCJMMOFMB-UHFFFAOYSA-M 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- WMJMABVHDMRMJA-UHFFFAOYSA-M [Cl-].[Mg+]C1CCCCC1 Chemical compound [Cl-].[Mg+]C1CCCCC1 WMJMABVHDMRMJA-UHFFFAOYSA-M 0.000 claims description 3
- PHSPFUQAZNIVCH-UHFFFAOYSA-M [Mg].[I-].C[N+]1=CC=CC=C1 Chemical compound [Mg].[I-].C[N+]1=CC=CC=C1 PHSPFUQAZNIVCH-UHFFFAOYSA-M 0.000 claims description 3
- HYGVRONUWGXDLF-UHFFFAOYSA-L magnesium;1,1'-biphenyl;dibromide Chemical compound [Mg+2].[Br-].[Br-].C1=CC=CC=C1C1=CC=CC=C1 HYGVRONUWGXDLF-UHFFFAOYSA-L 0.000 claims description 3
- IWCVDCOJSPWGRW-UHFFFAOYSA-M magnesium;benzene;chloride Chemical compound [Mg+2].[Cl-].C1=CC=[C-]C=C1 IWCVDCOJSPWGRW-UHFFFAOYSA-M 0.000 claims description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 claims description 3
- GFTXWCQFWLOXAT-UHFFFAOYSA-M magnesium;cyclohexane;bromide Chemical compound [Mg+2].[Br-].C1CC[CH-]CC1 GFTXWCQFWLOXAT-UHFFFAOYSA-M 0.000 claims description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims description 3
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 claims description 3
- GRYDGXUVWLGHPL-UHFFFAOYSA-M magnesium;heptane;bromide Chemical compound [Mg+2].[Br-].CCCCCC[CH2-] GRYDGXUVWLGHPL-UHFFFAOYSA-M 0.000 claims description 3
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 claims description 3
- YAMQOOCGNXAQGW-UHFFFAOYSA-M magnesium;methylbenzene;bromide Chemical compound [Mg+2].[Br-].CC1=CC=CC=[C-]1 YAMQOOCGNXAQGW-UHFFFAOYSA-M 0.000 claims description 3
- MPMNUCMJDPWNCV-UHFFFAOYSA-M magnesium;phenoxybenzene;bromide Chemical compound [Mg+2].[Br-].C=1C=[C-]C=CC=1OC1=CC=CC=C1 MPMNUCMJDPWNCV-UHFFFAOYSA-M 0.000 claims description 3
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 claims description 3
- ZKUUVVYMPUDTGJ-UHFFFAOYSA-N methyl 5-hydroxy-4-methoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC(O)=C(OC)C=C1[N+]([O-])=O ZKUUVVYMPUDTGJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 47
- 239000007788 liquid Substances 0.000 abstract description 6
- 239000000010 aprotic solvent Substances 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 abstract description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 abstract description 4
- 239000002699 waste material Substances 0.000 abstract description 3
- 239000007789 gas Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000007670 refining Methods 0.000 abstract description 2
- 238000005260 corrosion Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 150000002902 organometallic compounds Chemical class 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 38
- 239000000243 solution Substances 0.000 description 33
- 238000004128 high performance liquid chromatography Methods 0.000 description 28
- 239000002253 acid Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- 239000012065 filter cake Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 13
- -1 paracyanobenzoic acid methyl esters Chemical class 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 description 12
- 235000010755 mineral Nutrition 0.000 description 12
- 239000011707 mineral Substances 0.000 description 12
- 150000007524 organic acids Chemical class 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000012535 impurity Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 238000006298 dechlorination reaction Methods 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 description 7
- HQQARYRCDMYLHW-UHFFFAOYSA-N N,N-diethyl-2-[(2-methoxy-5-methylsulfonylbenzoyl)amino]ethanamine oxide Chemical compound CC[N+]([O-])(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC HQQARYRCDMYLHW-UHFFFAOYSA-N 0.000 description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 6
- 229940071870 hydroiodic acid Drugs 0.000 description 6
- 229910017604 nitric acid Inorganic materials 0.000 description 6
- STNAQENUCOFEKN-UHFFFAOYSA-N 2-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1C#N STNAQENUCOFEKN-UHFFFAOYSA-N 0.000 description 5
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- DTSJEZCXVWQKCL-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-(5-chloropyridin-2-yl)-2-[[4-(n,n-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide Chemical compound OC(=O)\C=C/C(O)=O.C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 DTSJEZCXVWQKCL-BTJKTKAUSA-N 0.000 description 4
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- GSJRUEBQWPLHSN-UHFFFAOYSA-N n-methylmethanamine;oxolane Chemical compound CNC.C1CCOC1 GSJRUEBQWPLHSN-UHFFFAOYSA-N 0.000 description 4
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- OZQXEOSNFMMMRD-UHFFFAOYSA-M [Cl-].CC(C)[Mg+].C1CCOC1 Chemical compound [Cl-].CC(C)[Mg+].C1CCOC1 OZQXEOSNFMMMRD-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 2
- NQBWNECTZUOWID-UHFFFAOYSA-N (E)-cinnamyl (E)-cinnamate Natural products C=1C=CC=CC=1C=CC(=O)OCC=CC1=CC=CC=C1 NQBWNECTZUOWID-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LXFSCSJMDZZGDN-UHFFFAOYSA-N COc(cc1)cc(C(Nc(nc2)ccc2Cl)=O)c1NC(c(cc1)ccc1C#N)=O Chemical compound COc(cc1)cc(C(Nc(nc2)ccc2Cl)=O)c1NC(c(cc1)ccc1C#N)=O LXFSCSJMDZZGDN-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 238000007445 Chromatographic isolation Methods 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229940059260 amidate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- NQBWNECTZUOWID-QSYVVUFSSA-N cinnamyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OC\C=C\C1=CC=CC=C1 NQBWNECTZUOWID-QSYVVUFSSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 2
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229960005219 gentisic acid Drugs 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- YSRKIFIAXKTQLN-UHFFFAOYSA-N CC[Zn]N(C)C Chemical compound CC[Zn]N(C)C YSRKIFIAXKTQLN-UHFFFAOYSA-N 0.000 description 1
- FITVBGDDRFHFKJ-UHFFFAOYSA-N CN(C)[Zn]C Chemical compound CN(C)[Zn]C FITVBGDDRFHFKJ-UHFFFAOYSA-N 0.000 description 1
- DJEYBELNUUJBQS-UHFFFAOYSA-N CN(C)[Zn]C1=CC=CC=C1 Chemical compound CN(C)[Zn]C1=CC=CC=C1 DJEYBELNUUJBQS-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- ZQSCEMYEJFSARK-UHFFFAOYSA-M O1CCCC1.[Br-].C(CCCC)[Mg+] Chemical compound O1CCCC1.[Br-].C(CCCC)[Mg+] ZQSCEMYEJFSARK-UHFFFAOYSA-M 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 231100001010 corrosive Toxicity 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to the fields of organic chemistry and pharmacy, and particularly relates to an improved method for preparing betrixaban. Compared with the prior art, the method has the advantages that the defects of use of high-corrosion hydrogen chloride gas, heavy burden for 'three wastes' treatment, difficult refining and purification of products and the like can be overcome. The method is characterized in that a metal organic compound RMR' (M is selected from Mg and Zn, R is selected from Cl, Br, I, alkyl or aryl, and R' is selected from akly or aryl) is used for reacting with dimethylamine or salt thereof in an aprotic solvent; then the obtained reacting liquid reacts with the compound or salt thereof in a formula II to prepare betrixaban. The improved novel method has the advantages of use of easily available raw materials, mild reaction condition, convenience in operation, excellent product quality and low cost and is suitable for industrial large-scale production.
Description
Technical field
The present invention relates to organic chemistry filed and pharmaceutical field, be specifically related to a kind of preparation method of improvement of betrixaban.
Background technology
Betrixaban (Betrixaban), chemistry is by name: N-(5-chloro-2-pyridyl)-2-[[4-[(dimethylamino) iminomethyl] benzoyl] is amino]-5-methoxy benzamide, and structure is such as formula shown in I:
Betrixaban, a kind of oral micromolecular compound, direct Xa factor inhibitor, is developed by Millennium the earliest, after transfer U.S. Portola Pharmaceuticals.This product is mainly used in the pulmonary embolisms that prevention and therapy dvt is formed and orthopedics is postoperative, can also be used for the apoplexy of preventing atrial fibrillation to cause simultaneously, can be used as the two wires prophylactic of myocardial infarction and apoplexy in addition.Abroad be in III phase clinical study at present.
Patent documentation CN1391555A, CN101595092A, CN102762538A etc. successively disclose the preparation method of betrixaban.
Patent documentation CN1391555A discloses following preparation method (square case 1) the earliest:
As shown in scheme 1, this technique is for raw material obtains compound V through amidate action under phosphorus oxychloride and pyridine condition with 2-amino-5-chloropyridine (VII) and 5-methoxyl group-2-nitrobenzoic acid (VI); Compound V obtains compound IV through tindichloride reduction; Compound IV with amidate action occurred to cyano-benzoyl chloride (III) obtain Compound II per; Thereafter, Compound II per first reacts in the hydrogen chloride methanol solution of high density, then sloughs the hydrogenchloride in reaction system, then reacts with dimethylamine, obtain betrixaban I finally by column chromatographic isolation and purification.This preparation technology's final step need use and process the hydrogen chloride gas of a large amount of highly corrosives, require high, and " three wastes " processing load is heavier to equipment anticorrosion; In addition, last column chromatographic isolation and purification is also unfavorable for industrialized enforcement.
For the deficiency of scheme 1 technique, patent documentation CN101595092A improves technique, wherein that the acid-reaction condition of final step has been replaced to basic reaction conditions the most significantly, namely first in tetrahydrofuran (THF) with base lithium and dimethylamine make dimethylin lithium just, then dimethylin lithium and Compound II per react, and be separated through aftertreatment and obtain betrixaban I, yield can reach 77%, HPLC purity about 98%, but wherein containing the dechlorination impurity about 1% shown in formula VIII.(square case 2).
As shown in scheme 2, the method not only avoid the use of strong caustic gas hydrogenchloride, reduces the burden that equipment anticorrosion processes with " three wastes "; And simplify post-processing operation, be conducive to industrial applications.But, the reagent that the method uses just base lithium expensive and transport storage requirement comparatively harsh, cause the production cost of product higher.In addition, the product that the method obtains contains the impurity of some more difficult removings, as dechlorination foreign matter content reaches 1%; Further, patent documentation CN102762538A also points out, two kinds of by products are easily generated when preparing betrixaban I by the method, i.e. dechlorination impurity VIII and demethyl impurity IX, even if through salify purifying, their content also may respectively up to 0.25%, and the generation of these and betrixaban I similar impurity is unfavorable for the raising of being further purified of betrixaban and refining yield.
Patent documentation CN102762538A discloses another syntheti c route (square case 3) of betrixaban.
As shown in Scheme 3, this technique is that condensation under coupling reagent exists obtains highly purified betrixaban I through compounds X and compound IV.Wherein compounds X adopts two kinds of methods to obtain: method one is, under the alkaline condition in similar such scheme 2, paracyanobenzoic acid ethyl ester (XII-I) is converted into compounds X I-I, and then compounds X I-I hydrolysis under lithium hydroxide exists obtains compounds X; Method two is, under the acidic conditions of similar such scheme 1 final step, paracyanobenzoic acid methyl esters (XII-II) is converted into compounds X I-II, and then compounds X I-II hydrolysis under lithium hydroxide exists obtains compounds X.The method adopts the route of convergence type to prepare betrixaban, is conducive to the shortening of preparation cycle.But its key intermediate compound X adopts the method for similar such scheme one or scheme two to prepare, and has the deficiency of aforesaid method.In addition, when compounds X is prepared in compounds X I-I or compounds X I-II hydrolysis, the amidino groups facile hydrolysis in its molecular structure is acid amides, causes the generation of more by product XIII, is unfavorable for the raising of reaction yield; In addition, because the polarity of compounds X is large, good water solubility, after it be hydrolyzed by compounds X I-I or compounds X I-II and obtains in lithium hydroxide aqueous solution, is not easily separated it, causes separation yield lower from reacting solution; Experiment shows that this one-step hydrolysis reaction gained compounds X crude product is about 50% to compounds X I-I or compounds X I-II separation yield.
Based on the deficiency of above betrixaban preparation method, the present inventor is studied its preparation method, have developed a kind of improvement novel method preparing betrixaban, these improvement novel method starting material are easy to get, reaction conditions is gentle, easy and simple to handle, good quality of product, cost is lower, is more suitable for industrialized production.
Summary of the invention
The novel method of the preparation that the object of the present invention is to provide a kind of betrixaban to improve.These improvement novel method starting material are easy to get, reaction conditions is gentle, easy and simple to handle, good quality of product, cost is lower, is more suitable for industrialized production.
In order to realize foregoing invention object, present invention employs following technical scheme:
The invention provides a kind of preparation method of formula I, the method comprises: by RMN (CH
3)
2react with formula II compound or its salt;
Wherein:
M is selected from Mg, Zn; R is selected from Cl, Br, I, alkyl or aryl; Wherein when R is alkyl, preferred C1-C7 straight or branched alkyl; When R is aryl, preferred phenyl or substituted-phenyl.In one embodiment, RMN (CH
3)
2for RMgN (CH
3)
2, be selected from ClMgN (CH
3)
2(dimethylin magnesium chloride), BrMgN (CH
3)
2(dimethylin magnesium bromide), IMgN (CH
3)
2(dimethylin magnesium iodide) etc.; In another embodiment, RMN (CH
3)
2for RZnN (CH
3)
2, be selected from CH
3znN (CH
3)
2(dimethylamino methyl zinc), CH
3cH
2znN (CH
3)
2(dimethylamino ethyl zinc), C
6h
5znN (CH
3)
2(dimethylaminophenyl zinc) etc.
In aforesaid method, RMN (CH
3)
2obtained by organometallics RMR ' and dimethylamine or its reactant salt; Wherein the definition of M and R is the same, and R ' is selected from alkyl or aryl; Wherein when R ' is for alkyl, preferred C1-C7 straight or branched alkyl; When R ' is for aryl, preferred phenyl or substituted-phenyl.In one embodiment, organometallics RMR ' is RMgR ', be selected from n-propyl magnesium chloride, isopropylmagnesium chloride, cyclohexyl magnesium chloride, phenyl-magnesium-chloride, benzylmagnesium chloride, methyl-magnesium-bromide, ethylmagnesium bromide, isopropyl magnesium bromide, selenium alkynide, n-pentyl magnesium bromide, cyclopentyl magnesium bromide, cyclohexyl magnesium bromide, n-heptyl magnesium bromide, o-tolyl magnesium bromide, 4-phenylbenzene magnesium bromide, 4-Phenoxyphenyl magnesium bromide, 4-flourophenyl magnesium bromide, 4-chlorophenylmagnesium bromide, methylpyridinium iodide magnesium etc., wherein preferred isopropylmagnesium chloride, isopropyl magnesium bromide or n-pentyl magnesium bromide, in one embodiment, organometallics RMR ' is RZnR ', is selected from zinc methide, zinc ethyl, phenylbenzene zinc etc., wherein preferred zinc ethyl.
The salt of dimethylamine refers to the salt that dimethylamine is formed with suitable mineral acid or organic acid; Wherein suitable mineral acid is selected from hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, phosphoric acid or sulfuric acid etc.; Suitable organic acid is selected from oxalic acid, acetic acid, trifluoroacetic acid, methylsulfonic acid, Phenylsulfonic acid, tosic acid etc.
Organometallics RMR ' is generally aprotic solvent with the solvent of dimethylamine or its reactant salt, be selected from tetrahydrofuran (THF), methyltetrahydrofuran, ether, methyl-phenoxide, methyl tertiary butyl ether, glycol dimethyl ether, Methylal(dimethoxymethane), diox, toluene, dimethylbenzene, hexane, heptane, hexanaphthene etc. or their mixed solvent, be wherein preferably tetrahydrofuran (THF), methyltetrahydrofuran, toluene.
Organometallics RMR ' is generally-10 DEG C to 40 DEG C with the temperature of reaction of dimethylamine or its salt, is preferably 0 DEG C to 30 DEG C.
Organometallics RMR ' is generally 1:1 to 1:3 with the molar ratio of dimethylamine, is preferably 1:1.1 to 1:1.5; If dimethylamine feeds intake in a salt form, so RMR ' generally needs Excess quantities to eliminate the impact of the reactive hydrogen of dimethylamine salt introducing, and the mole number of excessive portion is generally not less than the mole number of reactive hydrogen in dimethylamine salt.
After the reaction of organometallics RMR ' and dimethylamine or its salt completes, treatedly directly can not carry out subsequent reactions.
In aforesaid method, formula II compound or its salt can obtain according to method open in patent documentation CN1391555A, CN101595092A etc.
In aforesaid method, the salt of formula II compound refers to the salt that formula II compound is formed with suitable mineral acid or organic acid; Wherein suitable mineral acid is selected from hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, phosphoric acid or sulfuric acid etc.; Suitable organic acid is selected from oxalic acid, trifluoroacetic acid, methylsulfonic acid, Phenylsulfonic acid, tosic acid etc.
In aforesaid method, formula II compound and RMN (CH
3)
2molar ratio be generally 1:1 to 1:7, wherein preferred 1:2 to 1:6, if formula II compound feeds intake in a salt form, so RMN (CH
3)
2generally need Excess quantities to carry out the impact of the reactive hydrogen that cancelling II compound salt is introduced, the mole number of excessive portion is generally not less than the mole number of reactive hydrogen in formula II compound salt.
In aforesaid method, formula II compound or its salt and RMN (CH
3)
2reaction solvent be generally aprotic solvent, be selected from tetrahydrofuran (THF), methyltetrahydrofuran, ether, methyl-phenoxide, methyl tertiary butyl ether, glycol dimethyl ether, Methylal(dimethoxymethane), diox, toluene, dimethylbenzene, hexane, heptane, hexanaphthene etc. or their mixed solvent, be wherein preferably tetrahydrofuran (THF), methyltetrahydrofuran, toluene.
In aforesaid method, formula II compound or its salt and RMN (CH
3)
2temperature of reaction be generally-10 DEG C to 40 DEG C, be preferably 0 DEG C to 30 DEG C.
In aforesaid method, the determination in reaction times can adopt the method for this area routine to carry out, as adopted TLC, HPLC monitoring etc.
In aforesaid method, after the completion of reaction, can comprise further with the method for this area routine product is separated, the aftertreatment such as purifying; Such as, after reaction terminates, with acid (example hydrochloric acid, toxilic acid etc.) cancellation reaction, then operate separation through conventional concentrated, filtrations, washing etc. and obtain betrixaban or its salt.In one embodiment, after reaction terminates, with acid (example hydrochloric acid etc.) cancellation reaction, then obtain betrixaban I through the operation such as concentrated, filtration, washing separation, being greater than 80%, HPLC purity to the yield of Compound II per is greater than 98%; Further by conventional purification method such as recrystallizations, purifying is carried out to betrixaban, such as, the mixed solvent of available N,N-dimethylacetamide/toluene carries out further recrystallization purifying to betrixaban, and its HPLC purity can be increased to more than 99.0% or 99.5% or 99.7%.In another embodiment, after reaction terminates, with common medicine acid (as toxilic acid, hydrochloric acid etc.) cancellation reaction, then be separated through operations such as conventional concentrated, filtrations the salt obtaining betrixaban, 80%, HPLC purity be greater than to the yield of Compound II per and be greater than 98%; Further carry out purifying by conventional purification method such as recrystallizations to the salt of betrixaban, such as, the further recrystallization of the salt of mixed solvent to betrixaban of available alcohol/water, its HPLC purity can be increased to more than 99.0% or 99.5% or 99.7%.
In aforesaid method, optionally, by further for the betrixaban of gained salify.Formed salt generally refers to the salt that betrixaban is formed with suitable mineral acid or organic acid; Wherein suitable mineral acid is selected from hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, phosphoric acid or sulfuric acid etc.; Suitable organic acid is selected from toxilic acid, lactic acid, phenoxy acetic acid, propionic acid, succinic acid, hexanodioic acid, xitix, dextrocamphoric acid, gluconic acid, citric acid, methylsulfonic acid, fumaric acid, oxyacetic acid, naphthalene-1,5-disulfonic acid, gentisinic acid, Phenylsulfonic acid, camphorsulfonic acid, Alpha-hydroxy caproic acid, phenylformic acid, glucuronic acid, ketoglutaric acid, propanedioic acid, amygdalic acid, Pyrrolidonecarboxylic acid, styracin etc.The mode of salify generally comprises two kinds: one is after the completion of reaction, directly with suitable sour cancellation reaction salify simultaneously; Another kind is after reaction being terminated, and is first separated the betrixaban free alkali obtained, and then with suitable sour salify.The separation of salify or institute's salify can adopt the method for this area routine to carry out.
In one embodiment, the invention provides a kind of preparation method of formula I, the method comprises:
(1), by organometallics RMR ' and dimethylamine or its reactant salt; Wherein M is selected from Mg, Zn, and R is selected from Cl, Br, I, alkyl or aryl, and R ' is selected from alkyl or aryl;
(2), the dimethylamine reaction solution of step (1) gained and formula II compound or its salt are reacted.
In aforesaid method step (1), for convenience of description, by the reaction solution of organometallics RMR ' and dimethylamine or its reactant salt gained referred to as " dimethylamine reaction solution ".
In aforesaid method step (1), when R or R ' is for alkyl, preferred C1-C7 straight or branched alkyl; When R is aryl, preferred phenyl or substituted-phenyl.
In aforesaid method step (1), when organometallics RMR ' is for RMgR ', be selected from n-propyl magnesium chloride, isopropylmagnesium chloride, cyclohexyl magnesium chloride, phenyl-magnesium-chloride, benzylmagnesium chloride, methyl-magnesium-bromide, ethylmagnesium bromide, isopropyl magnesium bromide, selenium alkynide, n-pentyl magnesium bromide, cyclopentyl magnesium bromide, cyclohexyl magnesium bromide, n-heptyl magnesium bromide, o-tolyl magnesium bromide, 4-phenylbenzene magnesium bromide, 4-Phenoxyphenyl magnesium bromide, 4-flourophenyl magnesium bromide, 4-chlorophenylmagnesium bromide, methylpyridinium iodide magnesium etc., wherein preferred isopropylmagnesium chloride, isopropyl magnesium bromide or n-pentyl magnesium bromide, when organometallics RMR ' is RZnR ', be selected from zinc methide, zinc ethyl, phenylbenzene zinc etc., wherein preferred zinc ethyl.
In aforesaid method step (1), the salt of dimethylamine refers to the salt that dimethylamine is formed with suitable mineral acid or organic acid; Wherein suitable mineral acid is selected from hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, phosphoric acid or sulfuric acid etc.; Suitable organic acid is selected from oxalic acid, acetic acid, trifluoroacetic acid, methylsulfonic acid, Phenylsulfonic acid, tosic acid etc.
In aforesaid method step (1), reaction solvent is generally aprotic solvent, be selected from tetrahydrofuran (THF), methyltetrahydrofuran, ether, methyl-phenoxide, methyl tertiary butyl ether, glycol dimethyl ether, Methylal(dimethoxymethane), diox, toluene, dimethylbenzene, hexane, heptane, hexanaphthene etc. or their mixed solvent, be wherein preferably tetrahydrofuran (THF), methyltetrahydrofuran, toluene.
In aforesaid method step (1), temperature of reaction is generally-10 DEG C to 40 DEG C, is preferably 0 DEG C to 30 DEG C.
In aforesaid method step (1), organometallics RMR ' is generally 1:1 to 1:3 with the molar ratio of dimethylamine, is preferably 1:1.1 to 1:1.5; If dimethylamine feeds intake in a salt form, so RMR ' generally needs Excess quantities to eliminate the impact of the reactive hydrogen of dimethylamine salt introducing, and the mole number of excessive portion is generally not less than the mole number of reactive hydrogen in dimethylamine salt.
In aforesaid method step (1), after the reaction of organometallics RMR ' and dimethylamine or its salt completes, treatedly can not be directly used in the reaction of step (2).
In aforesaid method step (2), the salt of formula II compound refers to the salt that formula II compound is formed with suitable mineral acid or organic acid; Wherein suitable mineral acid is selected from hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, phosphoric acid or sulfuric acid etc.; Suitable organic acid is selected from oxalic acid, trifluoroacetic acid, methylsulfonic acid, Phenylsulfonic acid, tosic acid etc.
In aforesaid method step (2), the molar ratio of formula II compound and the middle organometallics RMR ' of step (1) is generally 1:1 to 1:7, wherein preferred 1:2 to 1:6; If formula II compound feeds intake in a salt form, so the organometallics RMR ' of organometallics RMR ' and corresponding dimethylamine or its salt and correspondence generally needs Excess quantities to carry out the impact of the reactive hydrogen that cancelling II compound salt is introduced, and the mole number of excessive portion is generally not less than the mole number of reactive hydrogen in formula II compound salt.
In aforesaid method step (2), reaction solvent is generally aprotic solvent, be selected from tetrahydrofuran (THF), methyltetrahydrofuran, ether, methyl-phenoxide, methyl tertiary butyl ether, glycol dimethyl ether, Methylal(dimethoxymethane), diox, toluene, dimethylbenzene, hexane, heptane, hexanaphthene etc. or their mixed solvent, be wherein preferably tetrahydrofuran (THF), methyltetrahydrofuran, toluene.
In aforesaid method step (2), temperature of reaction is generally-10 DEG C to 40 DEG C, is preferably 0 DEG C to 30 DEG C.
In aforesaid method step (2), the determination in reaction times can adopt the method for this area routine to carry out, as adopted TLC, HPLC monitoring etc.
In aforesaid method step (2), after the completion of reaction, can comprise further with the method for this area routine product is separated, the aftertreatment such as purifying; Such as, after reaction terminates, with acid (example hydrochloric acid, toxilic acid etc.) cancellation reaction, then operate separation through conventional concentrated, filtrations, washing etc. and obtain betrixaban or its salt.In one embodiment, after reaction terminates, with acid (example hydrochloric acid etc.) cancellation reaction, then obtain betrixaban I through the operation such as concentrated, filtration, washing separation, being greater than 80%, HPLC purity to the yield of Compound II per is greater than 98%; Further by conventional purification method such as recrystallizations, purifying is carried out to betrixaban, such as, the mixed solvent of available N,N-dimethylacetamide/toluene carries out further recrystallization purifying to betrixaban, and its HPLC purity can be increased to more than 99.0% or 99.5% or 99.7%.In another embodiment, after reaction terminates, with common medicine acid (example hydrochloric acid, toxilic acid etc.) cancellation reaction, then be separated through operations such as conventional concentrated, filtrations the salt obtaining betrixaban, 80%, HPLC purity is greater than to the yield of Compound II per and is greater than 98%; Further carry out purifying by conventional purification method such as recrystallizations to the salt of betrixaban, such as, the further recrystallization of the salt of mixed solvent to betrixaban of available alcohol/water, its HPLC purity can be increased to more than 99.0% or 99.5% or 99.7%.
In aforesaid method step (2), optionally, can salify further by the betrixaban of gained.Formed salt generally refers to the salt that betrixaban is formed with suitable mineral acid or organic acid; Wherein suitable mineral acid is selected from hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, phosphoric acid or sulfuric acid etc.; Suitable organic acid is selected from toxilic acid, lactic acid, phenoxy acetic acid, propionic acid, succinic acid, hexanodioic acid, xitix, dextrocamphoric acid, gluconic acid, citric acid, methylsulfonic acid, fumaric acid, oxyacetic acid, naphthalene-1,5-disulfonic acid, gentisinic acid, Phenylsulfonic acid, camphorsulfonic acid, Alpha-hydroxy caproic acid, phenylformic acid, glucuronic acid, ketoglutaric acid, propanedioic acid, amygdalic acid, Pyrrolidonecarboxylic acid, styracin etc.The mode of salify generally comprises two kinds: one is after the completion of reaction, with directly reacting salify simultaneously with suitable sour cancellation; Another kind is after reaction being terminated, and is first separated the betrixaban free alkali obtained, and then with suitable sour salify.The separation of salify or institute's salify can adopt the method for this area routine to carry out.
Above-mentioned betrixaban provided by the invention improves preparation method, compared with immediate prior art, in reaction conditions, quality product, product cost etc., has improvement effect.Such as:
As can be seen from upper table contrast, the reagent safety that improvement preparation method provided by the invention uses is better, cheaper, is conducive to the reduction of products production cost; And the product purity that this improvement preparation method obtains improves, dechlorination impurity VIII and the demethyl impurity IX of wherein more difficult removing significantly reduce, and are conducive to the preparation of pharmaceutical grade high purity betrixaban or its salt.
Generally speaking, the improvement preparation method starting material of above-mentioned betrixaban provided by the invention are easy to get, reaction conditions is gentle, easy and simple to handle, and good quality of product, cost is lower, is more suitable for industrialized production.
Accompanying drawing explanation
Fig. 1 betrixaban structural formula
Fig. 2 formula II structural formula of compound
Embodiment
Below in conjunction with the embodiment of embodiment, foregoing of the present invention is described in further detail again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example.Without departing from the idea case in the present invention described above, the various replacement made according to ordinary skill knowledge and customary means or change, all should comprise within the scope of the invention.
In following examples, mass spectroscopy is measured by the ESI ion source holotype of the mono-quadrupole mass spectrometer of Agilent 6120B; Nmr analysis is at room temperature, by BRUKER AVANCE III HD400 nuclear magnetic resonance analyser, and deuterated dimethyl sulfoxide (DMSO-d
6) make test solvent, in tetramethylsilane work, mapping completes surely.
The preparation of embodiment 1 betrixaban
Under stirring, temperature control 15 ~ 20 DEG C, drip isopropylmagnesium chloride tetrahydrofuran solution (can the commercialization buy) 308ml(0.615mol of 2mol/L, 5eq) to dimethylamine tetrahydrofuran solution (can the commercialization buy) 339ml(0.677mol of 2mol/L, 5.5eq), obtain dimethylamine reaction solution.
Under stirring, temperature control 15 ~ 20 DEG C, by formula II compound 50.0g(0.123mol, 1eq) mix with tetrahydrofuran (THF) 500ml, then drip above-mentioned dimethylamine reaction solution; Dropwise rear continuation stirring reaction at 25 ~ 30 DEG C, monitor reaction process with HPLC.After reaction terminates, at 15 ~ 20 DEG C, reaction solution is added in about 2mol/L aqueous hydrochloric acid 700ml, then use hydrochloric acid regulation system pH to 2 ~ 3; Concentrating under reduced pressure steams organic solvent, the solid of separating out in filtering and concentrating liquid, the appropriate water washing of filter cake; Filter cake and acetone 500ml are uniformly mixed, with triethylamine regulation system pH to 7 ~ 8; Filter; Filter cake is drying under reduced pressure at 40 ~ 45 DEG C, obtains betrixaban 45.5g.Yield: 82.0%; HPLC purity: 98.9%, wherein dechlorination impurity VIII is 0.05%, and demethyl impurity IX does not detect.
Get above-mentioned betrixaban 45.0g, stir at about 70 DEG C and be dissolved in N,N-dimethylacetamide 180ml, drip toluene 360ml; Cooling crystallization, filter, filter cake proper amount of acetone is washed, drying under reduced pressure at 40 ~ 45 DEG C; Gained betrixaban HPLC purity 99.7%.
(+)LC-MS:m/z=452([M+H]
+)。
1H NMR(400MHz,DMSO-d
6)δ:2.96(s,6H),3.83(s,3H),7.06-7.09(dd,1H),7.55-7.59(m,3H),7.80-7.83(dd,1H),8.21-8.23(d,1H),8.27-8.30(d,2H),8.37-8.40(d,1H),8.41-8.43(d,1H),10.54(br.,2H)。
The preparation of embodiment 2 betrixaban maleate
Under stirring, temperature control 0 ~ 5 DEG C, drips isopropylmagnesium chloride tetrahydrofuran solution (can commercialization buy) 105ml(0.21mol, the 8.4eq of 2mol/L) to dimethylamine hydrochloride 8.91g(0.11mol, in the suspension of tetrahydrofuran (THF) 60ml 4.4eq), obtain dimethylamine reaction solution.
Under stirring, temperature control 0 ~ 5 DEG C, by formula II compound 10.0g(0.025mol, 1eq) mix with tetrahydrofuran (THF) 100ml, then drip above-mentioned dimethylamine reaction solution; Dropwise rear continuation stirring reaction at 10 ~ 15 DEG C, monitor reaction process with HPLC.After reaction terminates, at 10 ~ 15 DEG C, reaction solution is added in the solution that toxilic acid 45g and aqueous solution 100ml is made into; Concentrating under reduced pressure steams organic solvent, the solid of separating out in filtering and concentrating liquid, the appropriate water washing of filter cake.Filter cake is drying under reduced pressure at 40 ~ 45 DEG C, obtains betrixaban maleate 12.1g.Yield: 85.4%; HPLC purity: 98.6%, wherein dechlorination impurity VIII is 0.03%, and demethyl impurity IX does not detect.
Get above-mentioned betrixaban maleate 10.0g, stir at about 70 DEG C and be dissolved in the mixed solvent of ethanol 50ml and water 25ml, drip water 150ml; Cooling crystallization, filter, filter cake is drying under reduced pressure at 40 ~ 45 DEG C; Gained betrixaban maleate HPLC purity 99.9%.
1H NMR(400MHz,DMSO-d
6)δ:3.25(s,3H),3.32(s,3H),3.87(s,3H),6.02(s,2H),7.19-7.21(dd,1H),7.44-7.45(1H),7.75-7.77(d,2H),7.97-9.98(d,2H),8.08-8.13(m,3H),8.44-8.45(d,1H),9.01(br.,1H),9.37(br.,1H),11.04(s,1H),11.13(s,1H).
The preparation of embodiment 3 betrixaban
Under stirring, temperature control 25 ~ 30 DEG C, drip isopropylmagnesium chloride tetrahydrofuran solution (can the commercialization buy) 81ml(0.161mol of 2mol/L, 7eq) to dimethylamine tetrahydrofuran solution (can the commercialization buy) 121ml(0.242mol of 2mol/L, 10.5eq), obtain dimethylamine reaction solution.
Under stirring, temperature control 25 ~ 30 DEG C, by formula II compound hydrochloride 10.0g(0.023mol, 1eq) mix with tetrahydrofuran (THF) 100ml, then drip above-mentioned dimethylamine reaction solution; Dropwise rear continuation stirring reaction at 25 ~ 30 DEG C, monitor reaction process with HPLC.After reaction terminates, at 15 ~ 20 DEG C, reaction solution is added in about 2mol/L aqueous hydrochloric acid 210ml, then use hydrochloric acid regulation system pH to 2 ~ 3; Concentrating under reduced pressure steams organic solvent, the solid of separating out in filtering and concentrating liquid, the appropriate water washing of filter cake; Filter cake and acetone 90ml are uniformly mixed, with triethylamine regulation system pH to 7 ~ 8; Filter; Filter cake is drying under reduced pressure at 45 ~ 50 DEG C, obtains betrixaban 8.35g.Yield: 80.5%.HPLC purity: 98.7%, wherein dechlorination impurity VIII is 0.03%, and demethyl impurity IX does not detect.
The preparation of embodiment 4 betrixaban hydrochloride
Under stirring, temperature control 15 ~ 20 DEG C, drip n-pentyl magnesium bromide tetrahydrofuran solution (can the commercialization buy) 75ml(0.075mol of 1mol/L, 3eq) to dimethylamine tetrahydrofuran solution (can the commercialization buy) 56ml(0.113mol of 2mol/L, 4.5eq), obtain dimethylamine reaction solution.
Under stirring, temperature control 15 ~ 20 DEG C, by formula II compound 10.0g(0.025mol, 1eq) mix with tetrahydrofuran (THF) 100ml, then drip above-mentioned dimethylamine reaction solution; Dropwise rear continuation stirring reaction at 25 ~ 30 DEG C, monitor reaction process with HPLC.After reaction terminates, at 15 ~ 20 DEG C, reaction solution is added in about 2mol/L aqueous hydrochloric acid 100ml, then use hydrochloric acid regulation system pH to 2 ~ 3; Concentrating under reduced pressure steams organic solvent, the solid of separating out in filtering and concentrating liquid, the appropriate water washing of filter cake.Filter cake is drying under reduced pressure at 40 ~ 45 DEG C, obtains betrixaban hydrochloride 10.1g, yield: 82.9%; HPLC purity: 99.0%, wherein dechlorination impurity VIII is 0.02%, and demethyl impurity IX does not detect.
Get above-mentioned betrixaban hydrochloride 10.0g, stir at about 70 DEG C and be dissolved in N,N-dimethylacetamide 40ml, drip toluene 80ml; Cooling crystallization, filter, filter cake is drying under reduced pressure at 40 ~ 45 DEG C; Gained betrixaban hydrochloride HPLC purity 99.8%.
The preparation of embodiment 5 betrixaban
Under stirring, temperature control 0 ~ 5 DEG C, drip toluene solution (can the commercialization buy) 50ml(0.050mol of the zinc ethyl of 1mol/L, 2eq) to dimethylamine tetrahydrofuran solution (can the commercialization buy) 28ml(0.055mol of 2mol/L, 2.2eq), obtain dimethylamine reaction solution.
Under stirring, temperature control 0 ~ 5 DEG C, by formula II compound 10.0g(0.025mol, 1eq) mix with tetrahydrofuran (THF) 100ml, then drip above-mentioned dimethylamine reaction solution; Dropwise rear continuation stirring reaction at 5 ~ 10 DEG C, monitor reaction process with HPLC.After reaction terminates, at 5 ~ 10 DEG C, reaction solution is added in about 2mol/L diluted hydrochloric acid aqueous solution 70ml, then use hydrochloric acid regulation system pH to 2 ~ 3; Concentrating under reduced pressure steams organic solvent, the solid of separating out in filtering and concentrating liquid, and appropriate water washing used successively by filter cake; Filter cake and acetone 100ml are uniformly mixed, with triethylamine regulation system pH to 7 ~ 8; Filter; Filter cake is drying under reduced pressure at 40 ~ 45 DEG C, obtains betrixaban 9.03g.Yield: 80.1%; HPLC purity: 99.0%, wherein dechlorination impurity VIII is 0.02%, and demethyl impurity IX does not detect.
The preparation of preparation example 1 formula II compound
(1) preparation of N-(the chloro-pyridine of 5--2-base)-5-methoxyl group-2-nitro-benzamide (compound V)
Under stirring at room temperature, by 5-methoxyl group-2-nitrobenzoic acid (compound VI, can commercialization buy) 250g(1.27mol, 1eq) with 2-amino-5-chloropyridine (compound VI I) 163g(1.27mol, 1eq) be suspended in acetonitrile 1700ml, add pyridine 301g(3.81mol, 3eq), then phosphorus oxychloride 231g(1.52mol, 1.2eq is dripped); Stirring reaction adds water 3500ml cancellation crystallization after 1 hour; Filter, filter cake use water 1700ml × 2 are washed; Drying under reduced pressure obtains compound V349g.
(2) preparation of 2-amino-N-(the chloro-pyridine of 5--2-base)-5-methoxy-b enzamide (compound IV)
Under stirring at room temperature, by N-(the chloro-pyridine of 5--2-base)-5-methoxyl group-2-nitro-benzamide (compound V) 300g(0.977mol, 1.0eq) be dissolved in acetic acid 3000ml, add iron powder 546g(9.77mol, 10eq) in batches; Continue stirring reaction after adding iron powder 3 hours, then add ethyl acetate 6000ml and water 3000ml, separatory; Aqueous phase ethyl acetate 3000ml × 2 extraction separated; Merge organic phase, successively with water, saturated aqueous solution of sodium bicarbonate, saturated sodium-chloride water solution washing, anhydrous sodium sulfate drying, concentrating under reduced pressure, obtains compound IV 244g.
(3) preparation of N-(the chloro-pyridine of 5--2-base)-2-(4-cyano-benzoyl-amino)-5-methoxy-b enzamide (Compound II per)
At 10 ~ 20 DEG C, by formula IV compound 200g(0.72mol, 1.0eq) with triethylamine 109g(1.08mol, 1.5eq) be dissolved in tetrahydrofuran (THF) 2000ml, drip cyano-benzoyl chloride (compound III wherein, can commercialization buy) 130g(0.79mol, 1.1eq) and the solution that is made into of tetrahydrofuran (THF) 1000ml, HPLC monitors reaction process; Reaction terminates rear filtration, and filter cake washs through ethanol in proper amount, and drying under reduced pressure obtains Compound II per 263g.HPLC purity: 98.7%.
(+)LC-MS:m/z=407([M+H]
+)。
1H NMR(400MHz,DMSO-d6)δ:3.85(s,3H),7.16-7.19(dd,1H),7.39-7.41(d,1H),7.93-7.96(d,2H),8.02-8.04(m,4H),8.13-8.14(d,2H),8.42-8.43(d,1H),11.06(br.2H)。
The preparation of preparation example 2 formula II compound hydrochloride
At 10 ~ 20 DEG C, by formula IV compound 40.0g(0.14mol, 1.0eq) be dissolved in tetrahydrofuran (THF) 400ml, drip cyano-benzoyl chloride (compound III wherein, can commercialization buy) 24.8g(0.15mol, solution 1.1eq) be made into tetrahydrofuran (THF) 200ml, HPLC monitors reaction process; Reaction terminates rear filtration, and filter cake washs through ethanol in proper amount, and drying under reduced pressure obtains formula II compound hydrochloride.HPLC purity: 99.5%.
Claims (13)
1. a preparation method for the improvement of betrixaban, is characterized in that RMN (CH
3)
2with formula
iIcompound or its salt reacts;
Wherein: M is selected from Mg, Zn; R is selected from Cl, Br, I, alkyl or aryl.
2. preparation method according to claim 1, is characterized in that described RMN (CH
3)
2be selected from ClMgN (CH
3)
2, BrMgN (CH
3)
2, IMgN (CH
3)
2, CH
3znN (CH
3)
2, CH
3cH
2znN (CH
3)
2or C
6h
5znN (CH
3)
2.
3. preparation method according to claim 1, is characterized in that described formula
iIcompound and RMN (CH
3)
2molar ratio be generally 1:1 to 1:7, preferred 1:2 to 1:6.
4. preparation method according to claim 1, is characterized in that the temperature of described reaction is-10 DEG C to 40 DEG C, is preferably 0 DEG C to 30 DEG C.
5. preparation method according to claim 1, is characterized in that described RMN (CH
3)
2obtained by organometallics RMR ' and dimethylamine or its reactant salt; Wherein the definition of M and R is the same, and R ' is selected from alkyl or aryl.
6. a preparation method for the improvement of betrixaban, is characterized in that adopting following methods:
(1), by organometallics RMR ' and dimethylamine or its reactant salt; Wherein M is selected from Mg, Zn, and R is selected from Cl, Br, I, alkyl or aryl, and R ' is selected from alkyl or aryl;
(2), by the dimethylamine reaction solution of step (1) gained and formula
iIcompound or its salt reacts.
7. according to the preparation method of claim 5 or 6, it is characterized in that described organometallics RMR ' is selected from n-propyl magnesium chloride, isopropylmagnesium chloride, cyclohexyl magnesium chloride, phenyl-magnesium-chloride, benzylmagnesium chloride, methyl-magnesium-bromide, ethylmagnesium bromide, isopropyl magnesium bromide, selenium alkynide, n-pentyl magnesium bromide, cyclopentyl magnesium bromide, cyclohexyl magnesium bromide, n-heptyl magnesium bromide, o-tolyl magnesium bromide, 4-phenylbenzene magnesium bromide, 4-Phenoxyphenyl magnesium bromide, 4-flourophenyl magnesium bromide, 4-chlorophenylmagnesium bromide, methylpyridinium iodide magnesium etc., wherein preferred isopropylmagnesium chloride, isopropyl magnesium bromide, n-pentyl magnesium bromide, zinc methide, zinc ethyl or phenylbenzene zinc, wherein preferred isopropylmagnesium chloride, isopropyl magnesium bromide, n-pentyl magnesium bromide or zinc ethyl.
8. according to the arbitrary described preparation method of claim 1,5 or 6, it is characterized in that the solvent of described reaction is selected from tetrahydrofuran (THF), methyltetrahydrofuran, ether, methyl-phenoxide, methyl tertiary butyl ether, glycol dimethyl ether, Methylal(dimethoxymethane), diox, toluene, dimethylbenzene, hexane, heptane, hexanaphthene or their mixed solvent, be wherein preferably tetrahydrofuran (THF), methyltetrahydrofuran, toluene.
9., according to the preparation method of claim 5 or 6, it is characterized in that described organometallics RMR ' is-10 DEG C to 40 DEG C with the temperature of reaction of dimethylamine or its salt, be preferably 0 DEG C to 30 DEG C.
10., according to the preparation method of claim 5 or 6, it is characterized in that described organometallics RMR ' is generally 1:1 to 1:3 with the molar ratio of dimethylamine, be preferably 1:1.1 to 1:1.5.
11. preparation methods according to claim 6, is characterized in that described step (2) Chinese style
iIthe molar ratio of compound and the middle organometallics RMR ' of step (1) is generally 1:1 to 1:7, preferred 1:2 to 1:6.
12. preparation methods according to claim 6, is characterized in that described step (2) temperature of reaction is-10 DEG C to 40 DEG C, are preferably 0 DEG C to 30 DEG C.
13., according to the preparation method of claim 1 or 6, is characterized in that further for the betrixaban of gained salify.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310664433.2A CN104693114B (en) | 2013-12-10 | 2013-12-10 | A kind of improved preparation method of betrixaban |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310664433.2A CN104693114B (en) | 2013-12-10 | 2013-12-10 | A kind of improved preparation method of betrixaban |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104693114A true CN104693114A (en) | 2015-06-10 |
CN104693114B CN104693114B (en) | 2019-08-16 |
Family
ID=53340709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310664433.2A Expired - Fee Related CN104693114B (en) | 2013-12-10 | 2013-12-10 | A kind of improved preparation method of betrixaban |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104693114B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105348187A (en) * | 2015-12-02 | 2016-02-24 | 安徽省逸欣铭医药科技有限公司 | Betrixaban structural analogue as well as preparation method and application thereof |
CN105732490A (en) * | 2016-03-25 | 2016-07-06 | 重庆医科大学 | Preparation method of betrixaban |
CN106518758A (en) * | 2015-09-11 | 2017-03-22 | 扬子江药业集团江苏紫龙药业有限公司 | Preparation method of Betrixaban intermediate N-(5-chloro-2-pyridyl)-2-(4-cyanobenzeneformamido)-5-metoxybenzamide |
CN106831553A (en) * | 2015-09-11 | 2017-06-13 | 天津科伦药物研究有限公司 | The preparation method of betrixaban or its analog |
WO2017117189A1 (en) * | 2015-12-30 | 2017-07-06 | Tetraphase Pharmaceuticals, Inc. | Preparation of mixed amidomagnesium halides |
CN107098853A (en) * | 2016-02-20 | 2017-08-29 | 天津科伦药物研究有限公司 | The preparation method of betrixaban maleate |
CN107778224A (en) * | 2016-08-31 | 2018-03-09 | 鲁南制药集团股份有限公司 | A kind of preparation method of betrixaban intermediate |
CN108530349A (en) * | 2018-04-09 | 2018-09-14 | 重庆三圣实业股份有限公司 | The preparation method and products thereof of betrixaban intermediate and betrixaban |
CN108586325A (en) * | 2017-03-16 | 2018-09-28 | 上海度德医药科技有限公司 | A kind of preparation method of Betrixaban intermediates |
WO2018229796A2 (en) | 2017-06-14 | 2018-12-20 | Mylan Laboratories Limited | A process for betrixaban hydrochloride and betrixaban maleate salt |
CN113620869A (en) * | 2020-05-06 | 2021-11-09 | 江西同和药业股份有限公司 | Preparation method of betrixaban |
CN114057607A (en) * | 2020-07-29 | 2022-02-18 | 鲁南制药集团股份有限公司 | Preparation method of betrixaban intermediate compound |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101595092A (en) * | 2006-11-02 | 2009-12-02 | 米伦纽姆医药公司 | The method of the pharmaceutical salts of composition-factor XA inhibitor |
WO2010132999A1 (en) * | 2009-05-21 | 2010-11-25 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
CN103261161A (en) * | 2010-09-01 | 2013-08-21 | 博尔托拉制药公司 | Crystalline forms of a factor Xa inhibitor |
-
2013
- 2013-12-10 CN CN201310664433.2A patent/CN104693114B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101595092A (en) * | 2006-11-02 | 2009-12-02 | 米伦纽姆医药公司 | The method of the pharmaceutical salts of composition-factor XA inhibitor |
WO2010132999A1 (en) * | 2009-05-21 | 2010-11-25 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
CN103261161A (en) * | 2010-09-01 | 2013-08-21 | 博尔托拉制药公司 | Crystalline forms of a factor Xa inhibitor |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106518758A (en) * | 2015-09-11 | 2017-03-22 | 扬子江药业集团江苏紫龙药业有限公司 | Preparation method of Betrixaban intermediate N-(5-chloro-2-pyridyl)-2-(4-cyanobenzeneformamido)-5-metoxybenzamide |
CN106831553A (en) * | 2015-09-11 | 2017-06-13 | 天津科伦药物研究有限公司 | The preparation method of betrixaban or its analog |
CN105348187A (en) * | 2015-12-02 | 2016-02-24 | 安徽省逸欣铭医药科技有限公司 | Betrixaban structural analogue as well as preparation method and application thereof |
CN105348187B (en) * | 2015-12-02 | 2017-12-08 | 安徽省逸欣铭医药科技有限公司 | A kind of betrixaban analogue and its production and use |
WO2017117189A1 (en) * | 2015-12-30 | 2017-07-06 | Tetraphase Pharmaceuticals, Inc. | Preparation of mixed amidomagnesium halides |
CN107098853A (en) * | 2016-02-20 | 2017-08-29 | 天津科伦药物研究有限公司 | The preparation method of betrixaban maleate |
CN105732490A (en) * | 2016-03-25 | 2016-07-06 | 重庆医科大学 | Preparation method of betrixaban |
CN107778224B (en) * | 2016-08-31 | 2020-06-26 | 鲁南制药集团股份有限公司 | Preparation method of betrixaban intermediate |
CN107778224A (en) * | 2016-08-31 | 2018-03-09 | 鲁南制药集团股份有限公司 | A kind of preparation method of betrixaban intermediate |
CN108586325A (en) * | 2017-03-16 | 2018-09-28 | 上海度德医药科技有限公司 | A kind of preparation method of Betrixaban intermediates |
WO2018229796A2 (en) | 2017-06-14 | 2018-12-20 | Mylan Laboratories Limited | A process for betrixaban hydrochloride and betrixaban maleate salt |
WO2018229796A3 (en) * | 2017-06-14 | 2019-01-24 | Mylan Laboratories Limited | A process for the preparation of betrixaban hydrochloride |
CN108530349A (en) * | 2018-04-09 | 2018-09-14 | 重庆三圣实业股份有限公司 | The preparation method and products thereof of betrixaban intermediate and betrixaban |
CN113620869A (en) * | 2020-05-06 | 2021-11-09 | 江西同和药业股份有限公司 | Preparation method of betrixaban |
CN113620869B (en) * | 2020-05-06 | 2023-04-18 | 江西同和药业股份有限公司 | Preparation method of betrixaban |
CN114057607A (en) * | 2020-07-29 | 2022-02-18 | 鲁南制药集团股份有限公司 | Preparation method of betrixaban intermediate compound |
Also Published As
Publication number | Publication date |
---|---|
CN104693114B (en) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104693114A (en) | Improved method for preparing betrixaban | |
CN105330609B (en) | A kind of method for preparing LCZ696 | |
CN104496979A (en) | Method for preparing oxazolidinone compound and intermediate thereof | |
US20130165675A1 (en) | Process for preparing aminobenzoylbenzofuran derivatives | |
CN103570530B (en) | A kind of preparation method of anidulafungin side chain intermediate | |
WO2017096772A1 (en) | Method for preparing anti-heart-failure medicine lcz696 | |
CN104447686B (en) | Polysubstituted 2-pyrroles's pyridine derivate and preparation method thereof | |
CN105330598A (en) | Preparing method for pirfenidone | |
CN112062712A (en) | Preparation method of 2- (5-bromo-3-methylpyridin-2-yl) acetic acid hydrochloride | |
CN104193765B (en) | A kind of synthetic method of cefixime | |
CN101108824B (en) | Method for synthesizing 2- chlorine -3- cyanogen radical pyridine with 3- cyanogen radical pyridine | |
CN108033990A (en) | The preparation method of Dexamethasone Intermediate | |
CN103880756A (en) | Preparation method of azilsartan intermediate | |
CN110028448B (en) | Preparation method of 3-hydroxy-2,3-dihydroisoquinoline-1, 4-diketone compound | |
CN104672180B (en) | Chiral preparation method of [(1S)-3-methyl-1-[[(2R)-2-methylepoxyethyl]carbonyl]butyl]tert-butyl carbamate | |
JP3874820B2 (en) | Method for producing taurine analogs | |
CN113372286A (en) | Method for preparing 1-phenyl-5-mercapto tetrazole by one-step method | |
CN115322191B (en) | Synthetic method of moxifloxacin hydrochloride | |
US20040053967A1 (en) | 3-(3-Amidinophenyl)-5-[({[1-(1-(iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same | |
CN112851508A (en) | Preparation method of Barosavir intermediate | |
CN105330525A (en) | Preparation method of 7-hydroxy-1-indanone | |
TWI685485B (en) | Processes to produce acalabrutinib | |
CN111057052B (en) | Method for preparing minodronic acid intermediate 2- (imidazo [1, 2-alpha ] pyridine-3-yl) acetate compound | |
JP6368717B2 (en) | Trifluoropyruvate derivative mixture and process for producing the same | |
CN111320622A (en) | Method for synthesizing moxifloxacin hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190816 |
|
CF01 | Termination of patent right due to non-payment of annual fee |